Literature DB >> 10791988

Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer.

T Hermiston1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10791988      PMCID： PMC315451          DOI： 10.1172/JCI9973

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  39 in total

Review 1.  Replication-selective adenoviruses as oncolytic agents.

Authors:  C Heise; D H Kirn
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 2.  Conditionally replicating herpes vectors for cancer therapy.

Authors:  R L Martuza
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 3.  Prodrug-activating systems in suicide gene therapy.

Authors:  C J Springer; I Niculescu-Duvaz
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 4.  Regulatable systems: applications in gene therapy and replicating viruses.

Authors:  S Agha-Mohammadi; M T Lotze
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 5.  Immunomodulation of cancer: potential use of selectively replicating agents.

Authors:  S Agha-Mohammadi; M T Lotze
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

6.  Adenovirus transcription. II. RNA sequences complementary to simian virus 40 and adenovirus 2DNA in AD2+ND1- and AD2+ND3-infected cells.

Authors:  S J Flint; Y Wewerka-Lutz; A S Levine; J Sambrook; P A Sharp
Journal:  J Virol       Date:  1975-09       Impact factor: 5.103

7.  Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization.

Authors:  K R Rogulski; M S Wing; D L Paielli; J D Gilbert; J H Kim; S O Freytag
Journal:  Hum Gene Ther       Date:  2000-01-01       Impact factor: 5.695

8.  Isolation of deletion and substitution mutants of adenovirus type 5.

Authors:  N Jones; T Shenk
Journal:  Cell       Date:  1978-01       Impact factor: 41.582

9.  B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells.

Authors:  R Y Chung; Y Saeki; E A Chiocca
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

10.  Use of nondefective adenovirus-simian virus 40 hybrids for mapping the simian virus 40 genome.

Authors:  T J Kelly; A M Lewis
Journal:  J Virol       Date:  1973-09       Impact factor: 5.103
View more
  32 in total

Review 1.  Prodrug-activating systems in suicide gene therapy.

Authors:  C J Springer; I Niculescu-Duvaz
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  A conditionally replicative adenovirus, CRAd-S-pK7, can target endometriosis with a cell-killing effect.

Authors:  A A V Paupoo; Z B Zhu; M Wang; D T Rein; A Starzinski-Powitz; D T Curiel
Journal:  Hum Reprod       Date:  2010-06-23       Impact factor: 6.918

3.  Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses for pan-carcinoma application.

Authors:  K Takayama; P N Reynolds; Y Adachi; L Kaliberova; J Uchino; Y Nakanishi; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-10-06       Impact factor: 5.987

Review 4.  Introduction to the background, principles, and state of the art in suicide gene therapy.

Authors:  Ion Niculescu-Duvaz; Caroline J Springer
Journal:  Mol Biotechnol       Date:  2005-05       Impact factor: 2.695

5.  Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program.

Authors:  Christopher L Morton; Peter J Houghton; E Anders Kolb; Richard Gorlick; C Patrick Reynolds; Min H Kang; John M Maris; Stephen T Keir; Jianrong Wu; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2010-08       Impact factor: 3.167

6.  Conditionally replicating adenovirus expressing TIMP2 for ovarian cancer therapy.

Authors:  Sherry W Yang; James J Cody; Angel A Rivera; Reinhard Waehler; Minghui Wang; Kristopher J Kimball; Ronald A Alvarez; Gene P Siegal; Joanne T Douglas; Selvarangan Ponnazhagan
Journal:  Clin Cancer Res       Date:  2010-11-29       Impact factor: 12.531

7.  Combing oncolytic adenovirus expressing Beclin-1 with chemotherapy agent doxorubicin synergistically enhances cytotoxicity in human CML cells in vitro.

Authors:  Li Li; Liang-Shun You; Li-Ping Mao; Shen-He Jin; Xiao-Hui Chen; Wen-Bin Qian
Journal:  Acta Pharmacol Sin       Date:  2017-09-14       Impact factor: 6.150

Review 8.  Gene therapy of benign gynecological diseases.

Authors:  Memy H Hassan; Essam E Othman; Daniela Hornung; Ayman Al-Hendy
Journal:  Adv Drug Deliv Rev       Date:  2009-05-13       Impact factor: 15.470

9.  Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors.

Authors:  Yonatan Y Mahller; Sachin S Vaikunth; Maria C Ripberger; William H Baird; Yoshinaga Saeki; Jose A Cancelas; Timothy M Crombleholme; Timothy P Cripe
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

10.  Developing novel oncolytic adenoviruses through bioselection.

Authors:  Wen Yan; Galila Kitzes; Farid Dormishian; Lynda Hawkins; Adam Sampson-Johannes; Josh Watanabe; Jenny Holt; Vivian Lee; Thomas Dubensky; Ali Fattaey; Terry Hermiston; Allan Balmain; Yuqiao Shen
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.